Concurrent pulmonary, hepatic and cerebral pneumocystosis: case report and review of the literature Authors: Hamed Chouaieb, Frédéric Méchaï, Marianne Ziol, Jean-François Behnam, Gilles Nevez, Solene Le Gal, Sophie Brun Published: 2026 ABSTRACT AbstractBackgroundPneumocystosis is a common opportunistic fungal infection primarily affecting immunocompromised individuals. While pulmonary involvement represents the most frequent presentation, extra pulmonary dissemination remains rare.Case presentationWe report herein an exceptional case of disseminated pneumocystosis in a patient living with HIV who presented with multiple symptoms including cough, dyspnea and generalized anasarca. Imaging tests showed pleural effusion with bilateral pulmonary parenchymal consolidations, marked splenomegaly with intra-parenchymal nodules, homogeneous hepatomegaly, and multiple cerebral lesions. Pneumocystis jirovecii was detected using qPCR in induced sputum and bronchoalveolar lavage fluid. Despite the initiation of appropriate treatment, the clinical course was progressive leading to the death of the patient. Gomori methenamine silver staining identified P. jirovecii asci in a liver biopsy performed one day before the patient died. qPCR assays performed retrospectively in cerebrospinal fluid, serum, and in paraffin-embedded hepatic tissue, were positive. The same multilocus genotype with a mutation in the dhps gene was identified in bronchoalveolar lavage fluid, serum, and liver biopsy specimens suggesting a disseminated infection due to a single strain of P. jirovecii.ConclusionsThis case highlights a rare and fatal presentation of disseminated pneumocystosis with the evidence of a single strain responsible for concurrent pulmonary, hepatic and blood involvement in a patient with advanced HIV-infection. It demonstrates the interest of P. jirovecii qPCR assays in organ and serum specimens to confirm histopathological and mycological diagnosis of this clinical presentation of the infection.Keywords: Extrapulmonary pneumocystosis, Disseminated pneumocystosis, Diagnosis, QPCR, Genotyping Background Pneumocystosis is an opportunistic fungal infection that affects particularly immunocompromised individuals, those with advanced HIV-infection or those treated with immunosuppressive and/or cytostatic therapies [1]. The incidence of Pneumocystis jirovecii infection has remarkably decreased in HIV-positive patients with the advent of antiretroviral therapy (ART) and the widespread adoption of prophylactic strategies. The lungs remain the most common site of infection, while extrapulmonary pneumocystosis has become extremely rare in the era of ART. Data on extrapulmonary pneumocystosis are scarce in literature [2]. We report herein an unusual and fatal case of disseminated pneumocystosis in a HIV-infected patient with the use of P. jirovecii qPCR assay for diagnosis in organ and serum specimens and multilocus genotyping demonstrating the presence of the same strain in infected organs and serum. Case presentation A 57-year-old patient with a history of HIV since 1994, who has discontinued medical follow-up for 10 years, was admitted in 2024 to Avicenne hospital, Bobigny, France, presenting with anasarca, likely due to profound hypoalbuminemia, hepatocellular failure and nephrotic syndrome, along with a deteriorated general condition and suspected myocarditis. The initial physical presentation revealed an emaciated patient with cough, dyspnea and significant oedema of the lower limbs. Chest computed tomography showed pleural effusion with bilateral pulmonary parenchymal consolidations. Abdominal images revealed a voluminous 17-cm splenomegaly with intra-parenchymal nodules and homogeneous hepatomegaly. Brain magnetic resonance imaging showed several supratentorial and subtentorial lesions with diffusion Hypersignal (Fig. 1). Radiological features associated with our case of disseminated pneumocystosis. a. Abdominal CT scan (contrast injection with portal-venous phase) showing splenic hypodense lesions; b. Chest CT scan showing consolidation of the right lower lobe; c. Magnetic resonance imagery (MRI) of the brain showing a right cerebellar lesion with hemorrhagic remodeling Laboratory test results revealed leukopenia at 2200 per mm3 with total lymphopenia at 340/mm3, a platelet count of 129,000/mm3, a prothrombin level of 43% associated with a decrease in vitamin K-dependent factors, creatinine at 88 µmol/L, and hepatic cytolysis with liver enzymes at 3 times the normal level. Additional lab results revealed: HIV viral load of 6.24 log/ml with a wild-type strain; CD4 lymphocytes < 20 cells/μL; HBV serology indicating resolved infection; positive HCV serology with undetectable HCV RNA; negative syphilis, HHV8 and HTLV1 serologies; negative CMV PCR. Blood and urine cultures carried out upon admission were negative. Additional findings included proteinuria of 3.7 g/24 h, albuminemia of 4 g/L, negative screening for active tuberculosis and initial LDH level of 529 IU/L. P. jirovecii was detected using a qPCR assay targeting the mitochondrial large subunit ribosomal RNA (mtLSU rRNA) in induced sputum and bronchoalveolar lavage fluid (BALF) performed on the same day, with a cycle threshold (Ct) at 22 and 16.9, respectively (RealStar® Pneumocystis jirovecii, Altona Diagnostics, Germany). The result of (1→3)-β-D-glucans in serum was highly positive with an index value > 4 (Fungitell STAT® assay, Associates of Cape Cod, USA, with a positivity threshold of 1.2), corresponding to a concentration > 500 pg/mL using the Fungitell® assay [3]. The treatment included high-dose intravenous cefotaxime (1 g ×3/day) and trimethoprim-sulfamethoxazole (TMP at 20 mg/kg/day and SMX at 100 mg/kg/day) for suspected bacterial pneumopathy or Pneumocystis Pneumonia (PCP). Despite antibiotic and antifungal treatment, the clinical course was unfavorable, with increased anasarca, somnolence and hemoptysis, leading to the patient’s death after 18 days in hospital. A liver biopsy performed the day before the patient died revealed on hematoxylin-eosin staining multiple necrotic foci in the lobule with fibrin deposit, without inflammatory infiltrate. Gomori methenamine silver staining revealed the presence of P. jirovecii asci in these foci (Fig. 2). The liver biopsy showed multiple necrotic foci with fibrin deposit with hematoxylin-eosin stain (a, arrows, x100) and gomori methenamine silver stain revealed round to oval and cup shaped positive asci of Pneumocystis jirovecii (b, arrows, x400) qPCR assays performed retrospectively in cerebrospinal fluid, serum, and in paraffin-embedded hepatic tissue were positive for P. jirovecii with Ct at 33.7, 22 and 15, respectively. P. jirovecii genotyping was performed using a multilocus sequence typing method (MLST) from extracted DNA of BALF, serum, liver biopsy, and cerebrospinal fluid specimens. Six loci, mtLSU rRNA, superoxide dismutase (sod), cytochrome b (cyb), inosine 5’ monophosphate dehydrogenase (impdh), dihydropteroate synthase (dhps), and dihydrofolate reductase (dhfr) genes, were analyzed as described elsewhere [4, 5]. MLST was unsuccessful in cerebrospinal fluid because of low fungal burden. The same multilocus genotype (mtLSU3-CYB1-SOD2-IMPDH-C, mutant dhps genotype at position 171, wild dhfr genotype) was identified in BALF, serum, and liver biopsy specimens suggesting a disseminated infection due to a single MLST/strain of P. jirovecii. Discussion and conclusions Extrapulmonary pneumocystosis is a rare manifestation of pneumocystosis since the widespread use of ART. This clinical presentation can develop in patients with or without concurrent pulmonary infection [6]. Extrapulmonary pneumocystosis occurs in patients with advanced HIV infection (CD4 < 200 cells/mm3), newly diagnosed, in absence of ART or with ART discontinuation. Although extrapulmonary pneumocystosis was reported in the late 1980s and early 1990s in patients receiving aerosolized pentamidine prophylaxis [2], cases have since been described in severely immunocompromised patients who were not exposed to aerosolized pentamidine. Currently, robust data showing that aerosolized pentamidine prophylaxis is a risk factor of extrapulmonary pneumocystosis are lacking. Other predisposing factors, besides advanced HIV infection, include solid organ transplantation, prolonged corticosteroid treatment, or hematologic malignancies [6]. Extrapulmonary pneumocystosis cases reported in the literature are summarized in Table 1. These cases have been identified in multiple tissues including liver, spleen, bile duct, intestine, lymph nodes, paravertebral soft-tissue, bones, bone marrow, central nervous system, adrenal glands and middle ear [2, 6–20]. Hepatic and cerebral pneumocystosis are rare manifestations. Central nervous system involvement with P. jirovecii generally occurs as a late complication of AIDS [7]. The generalized clinical presentations can affect multiple organs and present significant diagnostic challenges due to their non-specific symptoms and rarity. Around 60–64% of patients with extrapulmonary pneumocystosis exhibited involvement of multiple organs, either at connected or separate sites. Post-mortem findings indicated that dissemination could occur through hematogenous, lymphatic, or direct spread from neighboring organs [2, 6]. Dissemination via the hematogenous route was experimentally suggested by the presence of P. carinii DNA in non-pulmonary tissues in immunocompetent sentinel rats [21]. Table 1Summary of cases of extrapulmonary pneumocystosis reported in the literatureAuthors (Year of publication)CountryNumber of casesLocalization/clinical formPredisposing factorTreatmentOutcomeBartlett et al. (1997) [7]USA7Lungs (n = 5)Central nervous systemAIDS*Aerosolized pentamidine,TMP-SMX,Dapsone, and trimethoprimDeathHagmann et al. (2001) [8]USA1Intra-abdominal cystic lesionAIDS*TMP-SMP intravenous for 8 weeks.Oral regimen of TMP SMXResidual cyst without relapseAgarwal et al. (2001) [9]India1Adrenal glandsAlcoholAddison’s diseaseDouble-strength cotrimoxazole for 1 month.DeathMustafa et al. (2002) [10]USA1LungsBileAIDS*G6PD deficiencyTrimetrexateFavorable outcomePanos et al. (2007) [11]USA1Multi-skeletalAIDS*TMP-SMXDeathMahlakwane et al. (2008) [12]South Africa1LungsSpleenAIDS*LymphomaIntravenous pentamidine, prednisone andSplenectomyFavorable outcomeZhou et al. (2012) [13]USA (Ethiopian patient)1Small intestine pseudo-tumorAIDS*Not precisedNot precisedKaram et al. (2014) [14]Iran1BoneSpleenAIDS*TMP-SMXFavorable outcomeKim et al. (2018) [15]Korea1LiverAIDS*TMP-SMXFavorable outcomeSharma et al. (2019) [16]India1Adrenal glandsDiabetesTMP-SMX and clindamycin for 4 weeksRelapse after 5 months: primaquine and clindamycin for 4 weeksFavorable outcomeAbbas et al. (2020) [17]USA1LungsSpleenAIDS*TMP-SMXFavorable outcomeHasegawa et al. (2022) [18]Japan1SpleenLiverAdrenal glandsAIDS*TMP-SMX for 3 weeks,and CT-guided percutaneous catheter drainage of the splenic lesionwith intravenous pentamidine for 3 weeksFavorable outcomeKojima et al. (2023) [19]Japan1LungsSpleenAIDS*IRIS**TMP-SMX for 21 daysFavorable outcomeTancharoen et al. (2023) [6]Thailand1LungsParavertebralAIDS*TMP-SMX for 3 weeksFavorable outcomeCubides et al. (2025) [20]Colombia1LungsBone marrowAIDS*TMP-SMX and prednisolone for 3 weeksDeath*AIDS: Acquired Immunodeficiency Syndrome; **IRIS: Immune Reconstitution Inflammatory Syndrome Summary of cases of extrapulmonary pneumocystosis reported in the literature Lungs (n = 5) Central nervous system Aerosolized pentamidine, TMP-SMX, Dapsone, and trimethoprim TMP-SMP intravenous for 8 weeks. Oral regimen of TMP SMX Alcohol Addison’s disease Lungs Bile AIDS* G6PD deficiency Lungs Spleen AIDS* Lymphoma Intravenous pentamidine, prednisone and Splenectomy Bone Spleen TMP-SMX and clindamycin for 4 weeks Relapse after 5 months: primaquine and clindamycin for 4 weeks Lungs Spleen Spleen Liver Adrenal glands TMP-SMX for 3 weeks, and CT-guided percutaneous catheter drainage of the splenic lesion with intravenous pentamidine for 3 weeks Lungs Spleen AIDS* IRIS** Lungs Paravertebral Lungs Bone marrow *AIDS: Acquired Immunodeficiency Syndrome; **IRIS: Immune Reconstitution Inflammatory Syndrome As P. jirovecii cannot be obtained in long-term culture, diagnosis of extrapulmonary pneumocystosis requires a combination of imaging, histopathology, and mycology. Gomori methenamine silver (GMS), periodic acid-Schiff (PAS) or May Grunwald Giemsa staining are performed to reveal P. jirovecii asci (formerly cystic forms) and/or ascospores (formerly intra-cystic bodies) as well as trophic forms (formerly trophozoites) in different types of samples. However, obtaining samples from affected organs may be invasive and technically challenging. In addition, histopathological examination requires the expertise of practitioners. All of the published extrapulmonary pneumocystosis cases reported histopathological findings consistent with P. jirovecii presence in the affected organs but without molecular confirmation, except the study by Tancharoen et al. [6]. They reported the use of qPCR assay targeting the mtLSU rRNA gene for the detection of P. jirovecii in paraffin-embedded tissue of a paraspinal mass in the context of extrapulmonary pneumocystosis in an advanced HIV-infected patient. Efficiency of PCR assays in serum for PCP diagnosis has been studied but the results are still controversial [22–24]. There is not yet enough evidence to recommend the use of PCR assays in serum for PCP. In our case, the retrospective P. jirovecii qPCR in serum was strongly positive. This suggests the value of qPCR in serum as a reliable non-invasive marker for the diagnosis of extrapulmonary pneumocystosis. In addition, qPCRs in the liver and cerebrospinal fluid were also retrospectively positive, confirming the dissemination of fungi in extrapulmonary localizations. The qPCR assay in serum but also in organs other than respiratory organs could therefore be effective tools for the diagnosis of the dissemination of pulmonary pneumocystosis. We performed the genotyping of the dhps and dhfr genes of P. jirovecii in our patient. The MLST analysis showed the same multilocus genotype in BALF, serum, and liver biopsy specimens with the same mutation in dhps, suggesting a disseminated infection due to a single strain. The mutations in the dhps gene are spread worldwide and commonly associated with prior or ongoing sulfonamide treatment such as TMP-SMX, which targets the DHPS [25, 26]. The impact of DHPS mutations on treatment outcomes remains controversial. Indeed, mortality of AIDS-related PCP appears to be more closely linked to the initial clinical severity of the pneumonia rather than to the presence of mutations in DHPS. Moreover, DHPS mutations seem to be more associated with a loss of efficacy of TMP-SMX used in prophylaxis rather than in curative treatment [26]. In our patient, the identical DHPS mutation observed in all locations of infection (pulmonary, hepatic and blood) probably reflects the hematogenous dissemination of the initial P. jirovecii pulmonary strain. In extrapulmonary or disseminated PCP, especially when TMP-SMX is contraindicated or ineffective, alternative therapies are critical [27]. Intravenous pentamidine is the standard second-line option, though its use is limited by nephrotoxicity and hypoglycemia. Clindamycin-primaquine is another alternative, but primaquine may cause hemolysis in G6PD-deficient patients. Atovaquone is less effective for severe cases due to its oral route and slower action. Echinocandins, such as caspofungin, have been explored as adjunctive or salvage therapy in refractory or disseminated PCP, particularly in immunocompromised patients. Although not standard first-line agents, echinocandins may be considered in combination with other antipneumocystis drugs when response to conventional therapy is inadequate or in cases of extrapulmonary dissemination [28]. Recent studies, including a meta-analysis published in 2025, have evaluated the comparative efficacy and safety of treatment regimens for PCP, noting that echinocandins are generally reserved for salvage therapy or in cases of treatment failure [27]. Their role remains investigational, and clinical experience is limited, but they represent a valuable option in complex or refractory cases. This case highlights a rare and fatal presentation of disseminated pneumocystosis with the evidence of a single strain responsible for concurrent pulmonary, hepatic and blood involvement in a patient with advanced HIV-infection. It demonstrates the interest of P. jirovecii real-time PCR assays in organ and serum specimens to confirm histopathological and mycological diagnosis of this clinical presentation of the infection. The evaluation of the performance of the qPCR assay in serum to diagnose disseminated pneumocystosis will remain difficult given its low incidence and therefore the difficulty of including patients in an observational study. Nonetheless, this assay could provide a reliable and simple non-invasive alternative technique for diagnosing disseminated pneumocystosis, as it is already the case for invasive aspergillosis and mucormycosis. Early recognition, advanced molecular diagnosis, and resistance surveillance are key components to improve outcomes in such complex cases of disseminated pneumocystosis. Acknowledgements Not applicable. Author contributions HC wrote the 1st draft of the manuscript. FM wrote the clinical presentation of the patient. MZ performed the histological examination of the liver. JFB performed the real-time PCR assays. GN and SLG interpreted the genotyping data and substantively revised the manuscript. SB interpreted the mycological data and was a major contributor in writing the manuscript. All authors read and approved the final manuscript. All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. Funding Not applicable. Data availability Not applicable Declarations Ethics approval and consent to participate Not applicable Consent for publication In accordance with the French reference methodology MR-004, applicable to the retrospective use of health-related data, data and samples from a participant who died before or during the study may be used, provided that he did not express a written refusal during his lifetime. In our case, after being informed of the possible subsequent use of his data, the patient did not express any opposition during his entire hospital stay. In addition, written informed consent for publication was obtained from next of kin Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable